Sugi Predict

Sugi Predict / Compounds / SCHEMBL17618924

SCHEMBL17618924

SCHEMBL17618924

CC(C)n1cc(CC(N)C(=O)O)nn1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.45
▸ GRIA4 P48058 7/20 0.44
▸ GRIA1 P42261 6/20 0.44
▸ GRIA2 P42262 6/20 0.44
▸ GRIA3 P42263 6/20 0.44
▸ SLC1A3 P43003 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ ALPI P09923 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ XIAP P98170 1/20 0.39
▸ SLC7A5 Q01650 1/20 0.39
▸ GRIK1 P39086 1/20 0.38
▸ TYR P14679 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10129651 0.84 PTGS2 (0.34) ALDH1A1
SCHEMBL10059980 0.81 GRIA4 (0.54) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL19389423 0.81 GRIA4 (0.54) CYP1A2GRIA4GRIA1GRIA2GRIA3
Hydrochloric Acid SCHEMBL28699484 0.79 GRIA4 (0.53) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL13780804 0.79 CYP1A2 (0.43) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL19505363 0.78 GRIK1 (0.43) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL18659740 0.78 GRIK1 (0.43) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL10059442 0.78 GRIA4 (0.49) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL22434898 0.77 GRIK1 (0.42) CYP1A2GRIA4GRIA1GRIA2GRIA3
SCHEMBL18807553 0.77 CYP1A2 (0.44) CYP1A2GRIA4GRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSTY (US) 2024-02-27 — — US disclosed
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSTY (US) 2024-02-27 — — US disclosed
US-20230348405-A1 PSMA-TARGETING COMPOUNDS AND USES THEREOF THE JOHNS HOPKINS UNIVERSTY 2023-11-02 — — US disclosed
US-11661402-B2 PSMA-targeting compounds and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2023-05-30 — — US disclosed
US-20220135529-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY THE JOHNS HOPKINS UNIVERSTY 2022-05-05 — — US disclosed
US-11078166-B2 Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-08-03 — — US disclosed
US-20200360542-A1 SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY THE JOHNS HOPKINS UNIVERSTY 2020-11-19 — — US disclosed
US-20200290982-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY THE JOHNS HOPKINS UNIVERSTY 2020-09-17 — — US disclosed
US-10736974-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-11 — — US disclosed
EP-3536345-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY The Johns Hopkins University (US) 2019-09-11 — — EP disclosed
US-20190225589-A1 TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY 2019-07-25 — — US disclosed
US-10188754-B2 Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) THE JOHNS HOPKINS UNIVERSITY (US) 2019-01-29 — — US disclosed
US-20170333576-A1 NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2017-11-23 — — US disclosed
US-20170304433-A1 VACCINE COMPOSITIONS AND METHODS OF USE TO TREAT NEONATAL SUBJECTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-10-26 — — US disclosed
US-20170081298-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2017-03-23 — — US disclosed
WO-2017027870-A1 TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND \"REVERSED\" CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2017-02-16 — — WO disclosed
US-20160082132-A1 COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI) THE JOHNS HOPKINS UNIVERSITY (US) 2016-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081298-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY PSMA6, PSMA1, UTS2R CYP1A2 4817/4885GRIA4 2371/4885GRIA1 1261/4885
US-11078166-B2 Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof PAICS, FOLH1, UTS2R CYP1A2 4614/4885GRIA4 2824/4885GRIA1 2662/4885
US-20230348405-A1 PSMA-TARGETING COMPOUNDS AND USES THEREOF KLK3, FOLH1, SPR CYP1A2 4629/4885GRIA4 1786/4885GRIA1 1751/4885
US-20200360542-A1 SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY FOLH1, PSMA3, PSMA7 CYP1A2 4795/4885GRIA4 3445/4885GRIA1 3178/4885
US-20160082132-A1 COMPOSITIONS AND METHODS FOR CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MAGNETIC RESONANCE IMAGING (MRI) GART, SLC43A1, AADAT CYP1A2 1717/4885GRIA4 1798/4885GRIA1 1733/4885
US-20220135529-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY PSMA6, PSMA1, UTS2R CYP1A2 4812/4885GRIA4 2019/4885GRIA1 889/4885
US-11911488-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy FOLH1, PSMA3, PSMA7 CYP1A2 4795/4885GRIA4 3445/4885GRIA1 3178/4885
US-11661402-B2 PSMA-targeting compounds and uses thereof KLK3, FOLH1, SPR CYP1A2 4629/4885GRIA4 1786/4885GRIA1 1751/4885
US-10188754-B2 Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI) GART, SLC43A1, AADAT CYP1A2 1717/4885GRIA4 1798/4885GRIA1 1733/4885
US-20170333576-A1 NEW SCAFFOLDS AND MULTIFUNCTIONAL INTERMEDIATES FOR IMAGING PSMA AND CANCER THERAPY FOLH1, PSMA3, PSMA7 CYP1A2 4829/4885GRIA4 3408/4885GRIA1 3083/4885
US-20200290982-A1 METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY PSMA6, PSMA1, UTS2R CYP1A2 4812/4885GRIA4 2019/4885GRIA1 889/4885
US-10736974-B2 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy FOLH1, PSMA3, PSMA7 CYP1A2 4795/4885GRIA4 3445/4885GRIA1 3178/4885
US-20190225589-A1 TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF PAICS, FOLH1, UTS2R CYP1A2 4614/4885GRIA4 2824/4885GRIA1 2662/4885
US-20170304433-A1 VACCINE COMPOSITIONS AND METHODS OF USE TO TREAT NEONATAL SUBJECTS HLA-DRB1, ALPP, HLA-C CYP1A2 2499/4885GRIA4 3284/4885GRIA1 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.